Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.
Speakers: Prof. Steven Petrou, Director of the Florey and RogCon, Chief Scientific Officer, and Dr. Kiran Reddy, CEO of Praxis Precision Medicines. At the 2018 American Epilepsy Society meeting, Prof…
Genetic testing is complex. To decipher some of the terminolgy and help explain the process we talked to Dr Emma Palmer, Clinical Geneticist.
Children with developmental disabilities can have touble with sleep. Assoc Prof Margot Davey discusses what can be done to improve sleep in these children.
CURE Epilepsy has raised more than $60 million to fund epilepsy research. We talk with Dr Laura Lubbers about the work CURE Epilepsy is doing.
Working collaboratively has been one of the hallmarks of Prof Daniel Lowenstein’s career and has led to breakthrough research.
We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.
When Alex Nemiroff's son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.
Natural History Studies (NHS) are important in planning trials of treatment. We talk with Dr Katherine Howell, principal investigator of the SCN2A NHS.
Prof Ingrid Scheffer has published many key papers in SCN2A and genetic epilepsies and discusses the progress that has been made in understanding SCN2A.